Saltar al contenido

The Journal of Infectious Diseases

@jidjournal.bsky.social did:plc:j7joregvysxlyvog2l3xewmp

In publication since 1904, JID is the premier global journal for original research on infectious diseases. JID is an official journal of @idsainfo.bsky.social

En Bluesky desde el

Seguidores
6.861
Siguiendo
1
Posts
1.158
Días en rankings
0

Resumen

The Journal of Infectious Diseases (@jidjournal.bsky.social) es un usuario de Bluesky que se unió el 24 octubre 2023. Tiene 6.861 seguidores, sigue a 1 cuentas y ha publicado 1.158 posts.

Apariciones en rankings

Los mejores días en que los posts de esta cuenta entraron en la lista diaria de Debya.

Esta cuenta aún no ha aparecido en un ranking diario.

Posts que le gustaron recientemente

Me gusta públicos de la red Bluesky.

  • IDSA@idsainfo.bsky.social

    On IDSA’s & HIVMA’s Science Speaks blog: Learn more postnatal CMV infection in preterm infants, how rates of IPD since the COVID-19 pandemic shape vaccine recommendations and other research in @jidjournal.bsky.social ready to inform clinical practice. https://bit.ly/4BBski2

    Ver post
  • IDSA@idsainfo.bsky.social

    On IDSA’s & HIVMA’s Science Speaks blog: Check out insights from the editors of a new, ongoing series of articles in @cidjournal.bsky.social highlighting how experienced clinicians deploy problem-solving skills to navigate complex cases. https://bit.ly/48mkxr0

    Ver post
  • IDSA@idsainfo.bsky.social

    What happens when an antiviral works by causing mutations? In a new Let’s Talk ID episode, JID Deputy Editor Jonathan Li, MD, FIDSA talks the science behind molnupiravir and a recent paper that raised questions about its potential effects in mammalian cells. Watch: www.idsociety.org/multimedia/p...

    Ver post
  • IDSA@idsainfo.bsky.social

    On IDSA’s & HIVMA’s Science Speaks: Learn more about the efficacy of switching to doravirine/islatravir, how immunocompromised individuals hospitalized with COVID-19 remain at increased mortality risk and other research in @jidjournal.bsky.social to inform clinical practice. https://bit.ly/4AYYFzi

    Ver post
  • IDSA@idsainfo.bsky.social

    On IDSA’s & HIVMA’s Science Speaks blog: Learn about the poor antimalarial efficacy of IPTp-SP, how starting HIV treatment in early life can significantly reduce the size of the HIV reservoir and other new research in JID that’s ready to inform clinical practice. https://bit.ly/3SI2GGA

    Ver post

Inicia sesión para ver más

Cuentas que bloquea

En Bluesky los bloqueos son registros públicos.

Esta cuenta no bloquea a nadie.